Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

NCT02388906 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

906

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Ipilimumab
DRUG: Nivolumab
OTHER: Placebo matching Ipilimumab
OTHER: Placebo matching Nivolumab

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]